Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1391P - Clinical progress in inoperable or recurrent advanced gastric cancer treatment from 1,004 single institute experiences between 2007 and 2018

Date

16 Sep 2021

Session

ePoster Display

Topics

Cytotoxic Therapy;  Clinical Research

Tumour Site

Gastric Cancer

Presenters

Izuma Nakayama

Citation

Annals of Oncology (2021) 32 (suppl_5): S1040-S1075. 10.1016/annonc/annonc708

Authors

I. Nakayama1, D. Takahari1, K. Shimozaki1, K. Chin2, T. Wakatsuki2, A. Oki1, D. Kamiimabeppu2, H. Osumi1, M. Ogura1, E. Shinozaki1, K. Yamaguchi3

Author affiliations

  • 1 Gastroenterological Chemotherapy, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 2 Department Of Gastroenterology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 1358550 - Tokyo/JP
  • 3 Department Of Gastroenterological Chemotherapy, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 1358550 - Tokyo/JP

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1391P

Background

Several successes of clinical trials provide new agents into clinical practice of Advanced Gastric Cancer (AGC) over past ten years. It remains unknown whether these practice-changing results actually change our clinical practice.

Methods

We retrospectively reviewed previously untreated AGC patients who started combination chemotherapy of fluoropyrimidine and platinum between 2007 and 2018. We divided into three groups according to the starting periods. (Group A; 2007-2010, Group B; 2011-2014, Group C; 2015-2018) We compared the clinicopathological features, treatment details and clinical outcomes between three groups.

Results

A total of 1,004 consecutive patients were enrolled and 254 were classified into Group A, 300 were Group B and 450 were Group C respectively. There are more patients with poor performance status, aged, esophagogastric junction adenocarcinoma and primary tumor along with study period. Median overall survival (OS) of three groups were similar (approximately 16 months) and, the statistical differences in OS were not observed in any two groups. However, an improvement in OS between HER2 positive and negative was shown. (HER2 positive vs. negative in Group B; HR 0.80, 95% CI; 0.60-1.06 / Group C; HR 0.68, 95% CI; 0.51-0.90). Conversely, the survival of diffuse-type AGC was almost identical throughout the study period.

Conclusions

Increasing varieties of chemotherapy expanded indication of chemotherapy and change therapeutic strategy. The prolongation of survival could not be observed in the whole population past ten years but, clearly in HER2 positive AGC. Conversely, diffuse-type AGC remain dismal. Further development of biomarker-driven therapy would be warranted in future.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Japanese Foundation for Cancer Research.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.